Phase i trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

British Journal of Haematology

Volumn 147, Issue 1, 2009, Pages 89-96

  Barr, Paul M ^a   Fu, Pingfu ^b   Lazarus, Hillard M ^a   Horvath, Nancy ^a   Gerson, Stanton L ^a   Koc, Omer N ^c   Bahlis, Nizar J ^d   Snell, Michael R ^e   Dowlati, Afshin ^a   Cooper, Brenda W ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Fludarabine; Non Hodgkin lymphoma; Proteasome; Rituximab

Indexed keywords

BORTEZOMIB; BRYOSTATIN; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IBRITUMOMAB TIUXETAN; MELPHALAN; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; LYMPHOCYTOPENIA; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MAXIMUM TOLERATED DOSE; MOUTH INFECTION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; ORTHOSTATIC HYPOTENSION; PERIODONTITIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PYRAZINES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIDARABINE;

EID: 70349205461     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07836.x     Document Type: Article

References (36)

1. Adams, J., Palombella, V.J., Sausville, E.A., Johnson, J., Destree, A., Lazarus, D.D., Maas, J., Pien, C.S., Prakash, S. Elliott, P.J. (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research, 59, 2615 2622.
2. Barr, P., Fisher, R. Friedberg, J. (2007) The role of bortezomib in the treatment of lymphoma. Cancer Investigation, 25, 766 775.
3. Belch, A., Kouroukis, C.T., Crump, M., Sehn, L., Gascoyne, R.D., Klasa, R., Powers, J., Wright, J. Eisenhauer, E.A. (2007) A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology, 18, 116 121.
4. Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. Larson, R.A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 6 14.
5. Cairoli, R., Grillo, G., Tedeschi, A., D'Avanzo, G., Marenco, P. Morra, E. (2004) High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica, 89, 361 363.
6. Chaiwatanatorn, K., Lee, N., Grigg, A., Filshie, R. Firkin, F. (2003) Delayed-onset neutropenia associated with rituximab therapy. British Journal of Haematology, 121, 913 918.
7. Chaudhry, V., Cornblath, D.R., Polydefkis, M., Ferguson, A. Borrello, I. (2008) Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. Journal of the Peripheral Nervous System, 13, 275 282.
8. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
9. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology, 17, 1244 1253.
10. Czuczman, M.S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L., Bernstein, Z.P., McCarthy, P., Alam, A., Hernandez-Ilizaliturri, F., Skipper, M., Brown, K., Chanan-Khan, A., Klippenstein, D., Loud, P., Rock, M.K., Benyunes, M., Grillo-Lopez, A. Bernstein, S.H. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Journal of Clinical Oncology, 23, 694 704.
11. De Vos, S., Dakhil, S.R., McLaughlin, P., Saleh, M.N., Belt, R., Flowers, C., Holladay, C., Knapp, M., Boral, A., Zhang, T. Goy, A. (2006) Phase 2 study of bortezomib weekly or twice weekly plus rituximab in patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: final results. Blood (ASH Annual Meeting Abstracts), 108, 694.
12. Duechler, M., Linke, A., Cebula, B., Shehata, M., Schwarzmeier, J.D., Robak, T. Smolewski, P. (2005) In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. European Journal of Haematology, 74, 407 417.
13. Dunleavy, K., Pittaluga, S., Czuczman, M.S., Dave, S., Wright, G., Grant, N., Shovlin, M., Jaffe, E.S., Janik, J.E., Staudt, L.M. Wilson, W.H. (2009) Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B cell lymphoma. Blood, 113, 6069 6076.
14. Fisher, R.I., Bernstein, S.H., Kahl, B.S., Djulbegovic, B., Robertson, M.J., de Vos, S., Epner, E., Krishnan, A., Leonard, J.P., Lonial, S., Stadtmauer, E.A., O'Connor, O.A., Shi, H., Boral, A.L. Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 24, 4867 4874.
15. Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., Fayad, L.E., Bessudo, A., Camacho, E.S., Williams, M.E., van der Jagt, R.H., Oliver, J.W. Cheson, B.D. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology, 26, 204 210.
16. Gerecitano, J.F., Portlock, C., Hamlin, P., Moskowitz, C., Noy, A., Straus, D.J., Zelenetz, A.D., Schulman, P., Dumitrescu, O. O'Connor, O.A. (2008) A phase I study evaluating two dosing schedules of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) in patients with relapsed/refractory indolent and mantle cell lymphomas. Journal of Clinical Oncology (Meeting Abstracts), 26, 8512.
17. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J.E., Hagemeister, F., Fayad, L., Dang, N.H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Gilles, F., Sarris, A.H., Hart, S., Trehu, E., Schenkein, D., Cabanillas, F. Rodriguez, A.M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology, 23, 667 675.
18. Herrmann, A., Hoster, E., Zwingers, T., Brittinger, G., Engelhard, M., Meusers, P., Reiser, M., Forstpointner, R., Metzner, B., Peter, N., Wormann, B., Trumper, L., Pfreundschuh, M., Einsele, H., Hiddemann, W., Unterhalt, M. Dreyling, M. (2009) Improvement of overall survival in advanced stage mantle cell lymphoma. Journal of Clinical Oncology, 27, 511 518.
19. Hewamana, S., Alghazal, S., Lin, T.T., Clement, M., Jenkins, C., Guzman, M.L., Jordan, C.T., Neelakantan, S., Crooks, P.A., Burnett, A.K., Pratt, G., Fegan, C., Rowntree, C., Brennan, P. Pepper, C. (2008) The NF-[kappa]B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood, 111, 4681 4689.
20. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.-E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R. Unterhalt, M. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 106, 3725 3732. (Pubitemid 41742196)
21. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., Schlossman, R., Podar, K., Munshi, N.C., Mitsiades, N. Anderson, K.C. (2003) Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530 1534.
22. Horning, S.J. Rosenberg, S.A. (1984) The natural history of initially untreated low-grade non-Hodgkin's lymphomas. New England Journal of Medicine, 311, 1471 1475.
23. Horning, S.J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D. Goris, M. (2005) Efficacy and safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab. Journal of Clinical Oncology, 23, 712 719.
24. Kisselev, A.F. Goldberg, A.L. (2001) Proteasome inhibitors: from research tools to drug candidates. Chemistry & Biology, 8, 739 758.
25. Lemieux, B., Tartas, S., Traulle, C., Espinouse, D., Thieblemont, C., Bouafia, F., Alhusein, Q., Antal, D., Salles, G. Coiffier, B. (2004) Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation, 33, 921 923.
26. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.-T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377 2380.
27. Moosmann, P.R., Heizmann, M., Kotrubczik, N., Bargetzi, M. Wernli, M. (2008) Weekly treatment with a combination of bendamustine and bortezomib in relapsed or refractory indolent non-Hodgkin's lymphoma: a Single- Center Phase 1/2 Study. Blood (ASH Annual Meeting Abstracts), 112, 1574.
28. Mu, J.-J., Wang, Y., Luo, H., Leng, M., Zhang, J., Yang, T., Besusso, D., Jung, S.Y. Qin, J. (2007) A proteomic analysis of Ataxia Telangiectasia-mutated (ATM)/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. Journal of Biological Chemistry, 282, 17330 17334.
29. Nitta, E., Izutsu, K., Sato, T., Ota, Y., Takeuchi, K., Kamijo, A., Takahashi, K., Oshima, K., Kanda, Y., Chiba, S., Motokura, T. Kurokawa, M. (2007) A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Annals of Oncology, 18, 364 369.
30. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. Zelenetz, A.D. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676 684.
31. O'Connor, O.A., Smith, E.A., Toner, L.E., Teruya-Feldstein, J., Frankel, S., Rolfe, M., Wei, X., Liu, S., Marcucci, G., Chan, K.K. Chanan-Khan, A. (2006) The combination of the proteasome inhibitor bortezomib and the Bcl-2 antisense molecule oblimersen sensitizes human B-Cell lymphomas to cyclophosphamide. Clinical Cancer Research, 12, 2902 2911.
32. Strauss, S.J., Maharaj, L., Hoare, S., Johnson, P.W., Radford, J.A., Vinnecombe, S., Millard, L., Rohatiner, A., Boral, A., Trehu, E., Schenkein, D., Balkwill, F., Joel, S.P. Lister, T.A. (2006) Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. Journal of Clinical Oncology, 24, 2105 2112.
33. Tesfa, D., Gelius, T., Sander, B., Kimby, E., Fadeel, B., Palmblad, J. Hagglund, H. (2008) Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Medical Oncology, 25, 374 379.
34. Voog, E., Morschhauser, F., Solal-Celigny, P., Benyunes, M.C., Multani, P.S. Saunders, A. (2003) Neutropenia in patients treated with Rituximab. New England Journal of Medicine, 348, 2691 2694.
35. Wang, M., Han, X.H., Zhang, L., Yang, J., Qian, J.F., Shi, Y.K., Kwak, L.W., Romaguera, J. Yi, Q. (2008) Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia, 22, 179 185.
36. Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P.S. White, C.A. (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 3262 3269. (Pubitemid 34831524)